Literature DB >> 11257037

Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.

I A Leneva1, O Goloubeva, R J Fenton, M Tisdale, R G Webster.   

Abstract

In 1997, an avian H5N1 influenza virus, A/Hong Kong/156/97 (A/HK/156/97), caused six deaths in Hong Kong, and in 1999, an avian H9N2 influenza virus infected two children in Hong Kong. These viruses and a third avian virus [A/Teal/HK/W312/97 (H6N1)] have six highly related genes encoding internal proteins. Additionally, A/Chicken/HK/G9/97 (H9N2) virus has PB1 and PB2 genes that are highly related to those of A/HK/156/97 (H5N1), A/Teal/HK/W312/97 (H6N1), and A/Quail/HK/G1/97 (H9N2) viruses. Because of their similarities with the H5N1 virus, these H6N1 and H9N2 viruses may have the potential for interspecies transmission. We demonstrate that these H6N1 and H9N2 viruses are pathogenic in mice but that their pathogenicities are less than that of A/HK/156/97 (H5N1). Unadapted virus replicated in lungs, but only A/HK/156/97 (H5N1) was found in the brain. After three passages (P3) in mouse lungs, the pathogenicity of the viruses increased, with both A/Teal/HK/W312/97 (H6N1) (P3) and A/Quail/HK/G1/97 (H9N2) (P3) viruses being found in the brain. The neuraminidase inhibitor zanamivir inhibited viral replication in Madin-Darby canine kidney cells in virus yield assays (50% effective concentration, 8.5 to 14.0 microM) and inhibited viral neuraminidase activity (50% inhibitory concentration, 5 to 10 nM). Twice daily intranasal administration of zanamivir (50 and 100 mg/kg of body weight) completely protected infected mice from death. At a dose of 10 mg/kg, zanamivir completely protected mice from infection with H9N2 viruses and increased the mean survival day and the number of survivors infected with H6N1 and H5N1 viruses. Zanamivir, at all doses tested, significantly reduced the virus titers in the lungs and completely blocked the spread of virus to the brain. Thus, zanamivir is efficacious in treating avian influenza viruses that can be transmitted to mammals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257037      PMCID: PMC90446          DOI: 10.1128/AAC.45.4.1216-1224.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors.

Authors:  M Tisdale
Journal:  Rev Med Virol       Date:  2000 Jan-Feb       Impact factor: 6.989

2.  Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses.

Authors:  J K Dybing; S Schultz-Cherry; D E Swayne; D L Suarez; M L Perdue
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.

Authors:  M Aymard-Henry; M T Coleman; W R Dowdle; W G Laver; G C Schild; R G Webster
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

4.  Host range recombinants of fowl plague (influenza A) virus.

Authors:  C Scholtissek; I Koennecke; R Rott
Journal:  Virology       Date:  1978-11       Impact factor: 3.616

Review 5.  Pathogenicity of influenza virus.

Authors:  C Sweet; H Smith
Journal:  Microbiol Rev       Date:  1980-06

6.  Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates.

Authors:  Y P Lin; M Shaw; V Gregory; K Cameron; W Lim; A Klimov; K Subbarao; Y Guan; S Krauss; K Shortridge; R Webster; N Cox; A Hay
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

7.  H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China.

Authors:  Y Guan; K F Shortridge; S Krauss; P S Chin; K C Dyrting; T M Ellis; R G Webster; M Peiris
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Characterization of the influenza A virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1?

Authors:  E Hoffmann; J Stech; I Leneva; S Krauss; C Scholtissek; P S Chin; M Peiris; K F Shortridge; R G Webster
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Type A2 influenza viral infections in children.

Authors:  J W Paisley; F W Bruhn; B A Lauer; K McIntosh
Journal:  Am J Dis Child       Date:  1978-01

10.  Correlation of pathogenicity and gene constellation of influenza A viruses. III. Non-pathogenic recombinants derived from highly pathogenic parent strains.

Authors:  R Rott; M Orlich; C Scholtissek
Journal:  J Gen Virol       Date:  1979-08       Impact factor: 3.891

View more
  20 in total

1.  Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.

Authors:  Mitsutaka Kitano; Yasushi Itoh; Hirohito Ishigaki; Misako Nakayama; Hideaki Ishida; Van Loi Pham; Masahiko Arikata; Shintaro Shichinohe; Hideaki Tsuchiya; Naoko Kitagawa; Masanori Kobayashi; Ryu Yoshida; Akihiko Sato; Quynh Mai Le; Yoshihiro Kawaoka; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

Review 2.  Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease.

Authors:  Anne Moscona
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

3.  Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.

Authors:  Robert W Sidwell; Dale L Barnard; Craig W Day; Donald F Smee; Kevin W Bailey; Min-Hui Wong; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 4.  Zanamivir: an update of its use in influenza.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice.

Authors:  Yohichi Kumaki; John D Morrey; Dale L Barnard
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

6.  Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

Authors:  James J McSharry; Ann C McDonough; Betty A Olson; George L Drusano
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

Review 7.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

8.  Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005.

Authors:  Nguyen Duc Hien; Nguyen Hong Ha; Nguyen Tuong Van; Nguyen Thi Minh Ha; Trinh Thi Minh Lien; Nguyen Quoc Thai; Van Dinh Trang; Takuro Shimbo; Yoshimitsu Takahashi; Yasuyuki Kato; Akihiko Kawana; Samu Akita; Koichiro Kudo
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

Review 9.  Clinical review: update of avian influenza A infections in humans.

Authors:  Christian Sandrock; Terra Kelly
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

10.  The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.

Authors:  Martina Morokutti-Kurz; Marielle König-Schuster; Christiane Koller; Christine Graf; Philipp Graf; Norman Kirchoff; Benjamin Reutterer; Jan-Marcus Seifert; Hermann Unger; Andreas Grassauer; Eva Prieschl-Grassauer; Sabine Nakowitsch
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.